Trials / Completed
CompletedNCT00428220
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Conditions
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Metastatic Castration Resistant Prostate Cancer
- Metastatic Renal Cell Cancer
- Non-Small Cell Lung Cancer
- Thyroid Cancer
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Advanced Gastric Cancer
- Gastrointestinal Stromal Tumor
- Hepatocellular Carcinoma
- Pancreatic Islet Cell Carcinoma
- Pancreatic Neuroendocrine Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sunitinib | sunitinib |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2014-08-01
- Completion
- 2014-09-01
- First posted
- 2007-01-29
- Last updated
- 2019-06-27
- Results posted
- 2015-11-06
Locations
113 sites across 17 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hong Kong, Mexico, Philippines, Singapore, South Korea, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00428220. Inclusion in this directory is not an endorsement.